ClinicalTrials.gg
CompletedNCT03469960DICIPLEUpdated Nov 18, 2025

Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr

A Phase 3 interventional study of Ipilimumab and Nivolumab in Non-Small Cell Lung Cancer Metastatic, sponsored by Intergroupe Francophone de Cancerologie Thoracique. Completed at 47 sites in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Intergroupe Francophone de Cancerologie Thoracique · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
265
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 47 studies testing ipilimumab in Carcinoma, Non-Small-Cell Lung — 7 open to participants now, 13 under way, none of them phase 3. Ipilimumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
10th of 47
265 · median 39
Started
2018
with 6 others
Phase 3
10 of 47
none open now
Registered
27th of 47
by date

Among the 47 studies testing ipilimumab in Carcinoma, Non-Small-Cell Lung, this one is the 10th largest by enrollment, is one of 7 that started in 2018, is one of 10 in phase 3, and was the 27th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 47 studies testing ipilimumab in Carcinoma, Non-Small-Cell Lung are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About ipilimumab

Ipilimumab: first FDA approval 2011 (YERVOY), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing ipilimumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Non Small Cell lung cancer (NSCLC) remains the first cause of death by cancer in the World. For the patients presenting a NSCLC stage IV, the median of survival is about 15 months today. The chemotherapy with platinum is the standard treatment for these patients but immunotherapy showed these efficacy in 1st line for patients PD-L1 positive. On the other hand, the duration of treatment by immunotherapy is not clear. Indeed, prolonged responses and long survivals have been described in patients having interrupted the treatment. In the melanoma, a treatment of 6 months of ipilimumab demonstrated its efficacy. The objective of the study is to demonstrate that a treatment of 6 months followed by an observation (stop and go) is not less effective than a treatment given until progression or toxicity. This strategy would allow to decrease the accumulated toxicities, to improve the quality of life of the patients and to decrease the costs.

03

Conditions studied

  • Non-Small Cell Lung Cancer Metastatic

Keywords

  • IFCT
  • DICIPLE
  • NSCLC
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed Written :

    Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care.

    Subjects must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing.

  2. -proven NSCLC (squamous or non-squamous)
  3. Stage IV (M1, including M1a pleural involvement) disease (8th classification TNM, UICC 2015)
  4. PS \< 1
  5. Weight loss\< 10% in previous 3 months
  6. No prior systemic anticancer therapy (including EGFR or ALK inhibitors) given as primary therapy for advanced or disease.
  7. Age≥ 18 years, \<75 years
  8. > 3 months
  9. Measurable tumor disease by CT or MRI per 1.1 criteria
  10. Available tumor samples for centralized immunohistochemistry analysis
  11. PD-L1 tumor content ≥ 1% and \< 50% tumor cells as assessed locally by the investigator center
  12. Adequate biological functions:

    ≥ 50 mL/min (Cockcroft or or CKD-epi); neutrophiles ≥ 1500/mm3 ; ≥100 000/mm3 ; ≥ 9g/dL ; hepatic enzymes \< 3x , total ≤ 1,5 x ULN except for patients with proved, Gilbert syndrome (≤ 5 x ULN) or patients with hepatic metastases (≤ 3,0 mg/dL)

  13. Women of (WOCBP) and sexually active should use an efficacious method within the 28 days preceding the first dose and during the 6 months following the last dose of treatment. Women must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug.

    For Male subjects who are sexually active with WOCBP, an efficacious contraception method should be used during the treatment and during the 7 months following the last dose.

    Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy. Investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the use of highly effective methods of contraception. Highly effective methods of contraception have a failure rate of \< 1% when used consistently and correctly. At a minimum, subjects must agree to the use of two methods of contraception, with one method being highly effective and the other method being either highly effective or less effective.

  14. Patient inclusion validated by a multidisciplinary meeting.

Exclusion criteria

Exclusion Criteria:

  1. Small cell lung cancer or tumors with mixt histology including a SCLC component
  2. Known EGFR activating tumor mutation (deletion LREA in exon 19, L858R ou L861X mutations in exon 21, G719A/S mutation in exon 18) or HER exon 20 insertion (either tissue or plasma cfDNA mutation).
  3. Known ALK or ROS1 gene rearrangement as assessed by immunohistochemistry, FISH or NGS sequencing
  4. Previous or active cancer within the previous 5 years (except for treated carcinoma in situ of the cervix or basal cell skin cancer). Patients with a prostate adenocarcinoma history within the previous 5 years could be included in case of localized prostate cancer, with good prognostic factors according to d'Amico classification (≤ T2a and Score de Gleason ≤ 6 and PSA (ng/ml) ≤ 10), provided they were treated in a curative way (surgery or radiotherapy, without any chemotherapy)
  5. Superior vena cava (SVC) syndrome persisting after SVC stenting
  6. Thoracic radiotherapy needed at initiation of tumor treatment, except bone palliative radiotherapy on a painful or compressive , respecting 4 weeks delay between the end of radiotherapy and the beginning of induction immunotherapy treatment
  7. Symptomatic untreated (without previous whole brain radiotherapy or stereotactic ablative brain radiotherapy or without surgical resection). At least 4 weeks delay between the end of radiotherapy and the beginning of induction immunotherapy treatment should be respected. Asymptomatic brain metastasis, not needing greater than 10 mg prednisone equivalent daily or mannitol infusions, with no evolution on brain MRI or CT-scan within the previous month are allowed.
  8. History of previous primary immunodeficiency, organ transplantation needing an treatment, any immunosuppressive drug within 28 days before randomization date, or history of severe toxicity (grade 3/4) by immune mechanism linked to another immunotherapy treatment.
  9. Systemic treatment with corticosteroids with greater dose than 10 mg prednisone equivalent daily, within 14 days before initiation of the immunotherapy induction. Inhaled, nasal or topic corticosteroids are allowed.
  10. History of active disease including rheumatoid polyarthritis, Lupus, Wegener disease. Patients with type I diabetes, or hypothyroidism, or immune cutaneous disease (vitiligo, psoriasis, alopecia) not needing any immunosuppressive systemic treatment, are allowed to be included.
  11. Active inflammatory intestinal disease (diverticulosis, Crohn disease, Hemorrhagic recto-colitis, coeliac disease) or any serious chronic intestinal disease with uncontrolled diarrhea
  12. Active uncontrolled infection including tuberculosis, known acute viral and C according to serological tests. Patients with serological sequelae of cured viral hepatitis are allowed to be included.
  13. known infection
  14. Living attenuated vaccine received within the 30 previous days
  15. Previous treatment with , anti-PD-L1 or Anti-CTLA4 antibody
  16. Previous treatment with chemotherapy
  17. General serious condition such as congestive uncontrolled cardiac failure, uncontrolled cardiac arrythmia, uncontrolled ischemic cardiac disease (unstable angina or history of myocardial infarction in the previous 6 months), history or stroke within the 6 previous months
  18. Pre-existing lung interstitial disease as assessed by the diagnosis CT-scan.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
265 participants (actual)

Study arms

  • Active comparator
    Arm A : standard treatment

    6 months of treatment by nivolumab + ipilimumab then nivolumab + ipilimumab then in case of progression platinum-based doublet recommended

    Drug: Ipilimumab · Drug: Nivolumab

  • Experimental
    Arm B : experimental arm

    6 months of treatment by nivolumab + ipilimumab then observation the in case of progression nivolumab + ipilimumab then in case of progression platinum-based doublet recommended

    Drug: Ipilimumab · Drug: Nivolumab

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS1)

    Time between the date of randomization and the first date of documented progression, as determined by BICR (Blinded Independent Central Review), or death due to any cause, whichever occurs first.

    Time frame: 24 months after randomization of the last subject

Secondary outcomes

  1. Progression Free Survival (PFS2)

    Time between the start date of the second line and the second date of documented progression, as determined by BICR, or death due to any cause, whichever occurs first.

    Time frame: 24 months after randomization of the last subject

  2. Quality of life (QoL)

    Time until definitive deterioration (TUDD) from the randomization time in the experimental arm B.

    Time frame: 24 months after randomization of the last subject

  3. Overall survival (OS)

    Time frame: 6, 12 and 18 months after randomization

  4. Biological correlative exploratory studies (PD-L1)

    PD-L1-stained % of tumor cells will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS

    Time frame: 6 months

  5. Biological correlative exploratory studies (PD-L1 H score)

    PD-L1 H-score will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS

    Time frame: 6 months

  6. Biological correlative exploratory studies (CD3/CD8)

    CD3/CD8 tumor infiltration will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS

    Time frame: 6 months

  7. Biological correlative exploratory studies (neutrophil)

    neutrophil tumor infiltration will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS

    Time frame: 6 months

  8. Biological correlative exploratory studies (cytokines)

    plasma concentration of different cytokines at baseline or at the randomization point, will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS

    Time frame: 6 months

  9. Biological correlative exploratory studies (chemokines)

    plasma concentration of different chemokines at baseline or at the randomization point, will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS

    Time frame: 6 months

07

Study locations

47 sites
  • Amiens - CHU
    Amiens, France
  • Angers - CHU
    Angers, 49000, France
  • Annecy - CH
    Annecy, 74374, France
  • Argenteuil -CH
    Argenteuil, 95100, France
  • Avignon - CH
    Avignon, France
  • Bordeaux - Polyclinique Nord
    Bordeaux, France
  • Boulogne - Ambroise Paré
    Boulogne-Billancourt, France
  • Caen - CHU Côte de Nacre
    Caen, 14000, France
  • Cahors - CH
    Cahors, 46000, France
  • CH de Pontoise
    Cergy-Pontoise, France
  • CH Chambery
    Chambéry, France
  • CH de Chauny
    Chauny, France
  • CH
    Cholet, France
  • Clamart - Hôpital Percy
    Clamart, 92140, France
  • Clermont Ferrand - CHU
    Clermont-Ferrand, 63000, France
  • Colmar - CH
    Colmar, 68000, France
  • Dijon - CAC
    Dijon, 21000, France
  • CHRU Grenoble
    Grenoble, France
  • La Roche Sur Yon - CH
    La Roche-sur-Yon, 85925, France
  • Centre Hospitalier - Pneumologie
    Le Mans, 72000, France
  • CHRU de Lille
    Lille, France
  • CHU de Limoges
    Limoges, France
  • CH Lyon Sud - Pneumologie
    Lyon, France
  • Institut Paoli Calmette
    Marseille, France
  • Marseille - Hôpital Européen
    Marseille, France
  • Mont de Marsan - CH
    Mont-de-Marsan, 40000, France
  • Mulhouse - CH
    Mulhouse, 68000, France
  • Nantes - Centre René Gauducheau
    Nantes, 44805, France
  • Centre Antoine Lacassagne
    Nice, France
  • CHU Nîmes
    Nîmes, France
  • Orléans - CH
    Orléans, 45000, France
  • AP-HP Hopital Tenon - Pneumologie
    Paris, 75020, France
  • AP-HP Hôpital Bichat
    Paris, France
  • GH Paris Saint-Joseph
    Paris, France
  • Hôpital Saint Louis APHP
    Paris, France
  • Paris - Institut Curie
    Paris, France
  • Rouen - CHU
    Rouen, 76000, France
  • Centre René Huguenin
    Saint-Cloud, France
  • HIA Begin
    Saint-Mandé, France
  • ICL Lucien Neuwirth
    Saint-Priest-en-Jarez, France
  • Saint Quentin - CH
    Saint-Quentin, 02100, France
  • Suresnes - Hopital Foch
    Suresnes, 92151, France
  • Toulon - CHI
    Toulon, 83000, France
  • CHU Toulouse
    Toulouse, France
  • CHRU de Tours
    Tours, France
  • Versailles - CH
    Versailles, 78157, France
  • CH de Villefranche - Pneumologie
    Villefranche, France
08

References and documents

Related links

Individual participant data

Plan to share: Yes — The individual participant data underlying the results reported in this article, as well as the study protocol and statistical analysis plan, will be made available after deidentification immediately following publication and for three years. Researchers who provide a methodologically sound proposal for any purpose may direct proposals to contact@ifct.fr. To gain access, data requestors will need to sign a data access agreement that requires approval by the French Cooperative Thoracic Intergroup.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Nov 2023, 66 months.

Of 109 non-industry phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 129. This study's 66 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2018
First posted
Mar 19, 2018
StartActual
May 2, 2018
Primary completionActual
Nov 8, 2023
CompletionActual
Oct 15, 2025
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03469960
Lead sponsor
Intergroupe Francophone de Cancerologie Thoracique
Responsible party
Sponsor
First posted
Mar 19, 2018
Start date
May 2, 2018
Primary completion
Nov 8, 2023
Completion
Oct 15, 2025
Last update
Nov 18, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ipilimumab · Nivolumab

Start the discussion